These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 2000655)

  • 1. [Severe nortriptyline poisoning in poor metabolizers of the sparteine type].
    Petersen P; Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):443-4. PubMed ID: 2000655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Insufficient effect of nortriptyline in a rapid metabolizer of sparteine].
    Stage KB; Brøsen K
    Ugeskr Laeger; 1993 May; 155(20):1561-3. PubMed ID: 8316990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.
    Jornil J; Jensen KG; Larsen F; Linnet K
    Eur J Pharm Sci; 2011 Oct; 44(3):265-72. PubMed ID: 21854846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
    Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
    Fromm MF; Hofmann U; Griese EU; Mikus G
    Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
    Kaneko K; Atsumi T; Miyataka T
    Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
    Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
    Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
    Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
    Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.
    Ebner T; Meese CO; Eichelbaum M
    Mol Pharmacol; 1995 Dec; 48(6):1078-86. PubMed ID: 8848008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biotransformation of sparteine in the Cuna American Indians of Panama].
    Arias TD; Jorge L; Lee D; Guerrero de Solís N; Escobar J; Barrantes R; Inaba T
    Rev Med Panama; 1986 Sep; 11(3):199-209. PubMed ID: 3468564
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
    Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
    Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
    Pedersen RS; Damkier P; Brosen K
    Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.